A 2022 rebuttal to a regional newspaper opinion piece on vaping risks and the black market
Source material dated August 2022 · Research evidence
Overview
In August 2022 the source published a rebuttal to an opinion piece in a Tasmanian newspaper written by two authors who opposed vaping. The source said the newspaper had not acted on a request to correct errors, so it set out its objections itself. It argued the original piece overstated vaping risks, and it used strong language about the article that this summary does not repeat. The points below are the source's position on each claim.
Risk claims
The newspaper piece had said e-cigarettes would likely cause several cancers, cardiovascular disease and stroke, and could worsen COVID-19 symptoms. The source said there was no evidence for these statements. It cited an estimate that cancer risk from vaping is under 0.5 per cent of the risk from smoking and a UK medical college view that long-term vaping is likely to carry no more than 5 per cent of smoking's risk. It added that studies had found no link between e-cigarette use and COVID-19 risk, and that smokers who switch have shown improved blood pressure. It also accepted that not everything about vaping is known and that avoiding both smoking and vaping is best.
Quitting and population effects
The source disputed the claim that evidence on quitting with e-cigarettes is thin. It cited clinical trials and real-world experience suggesting a quit advantage of 50 to 100 per cent over nicotine replacement, and a review of 171 trials that ranked vaping first among cessation treatments. It also cited modelling in the United States estimating 1.8 million premature deaths avoided between 2013 and 2060, and argued that exposure to many toxins in smoke should be compared with exposure to trace levels in vapour.
Illicit supply
The newspaper piece had said the tobacco industry fuelled the black market. The source disagreed, saying illicit vapes were cheap imports from other makers and that the prescription-only model had left a gap that the black market filled, including sales to children.
Context and limits
This is one side of an exchange in the public record, and the original newspaper piece is not reproduced here. The cited figures, modelling and estimates are the source's choices and rest on assumptions. Other researchers draw different conclusions from the same literature.
Based on a 2022 blog post responding to a newspaper opinion article.
Related summaries
- A 2025 randomised trial of vaping versus nicotine replacement among disadvantaged smokers
- A 2024 British medical college report on e-cigarettes and harm reduction
- Tobacco industry transformation and nicotine: a 2023 rebuttal
- Four researchers' 2023 evidence review of nicotine vaping for lawmakers